DNLI
NASDAQ
US
Denali Therapeutics Inc. - Common Stock
$20,65
▲ +$0,97
(+4,93%)
Vol 1.6M
3
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$2.6B
ROE
-40,8%
Margin
-36,5%
D/E
0,60
Beta
0,98
52W
$11–$24
Konsensus Wall Street
25 analis · Apr 202611
Beli Kuat
12
Beli
2
Tahan
0
Jual
0
Jual Kuat
92,0%
Peringkat Beli
Grafik Harga
Saham Serupa
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17,3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13,2
$2.9B
ARQT
Arcutis Biotherapeutics Inc
$3.6B
VERA
Vera Therapeutics, Inc
$3.5B
Pendapatan
Tingkat beat: 75,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $-0,76 | $-0,73 | +$0,03 |
| Sep 2025 | $-0,77 | $-0,74 | +$0,03 |
| Jun 2025 | $-0,73 | $-0,72 | +$0,01 |
| Mar 2025 | $-0,70 | $-0,78 | $-0,08 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Pendapatan | — | — | — | — | — |
| Laba Bersih | -$114.8M | -$133.0M | -$124.1M | -$126.9M | -$128.5M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -40.8% | -31.4% | -31.4% | -31.4% | -40.8% | -40.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -36.5% | -36.5% | -36.5% | -36.5% | -36.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.54 | 0.54 | 0.54 | 0.54 | 0.60 | 0.60 |
| Current Ratio | 10.27 | 10.27 | 10.27 | 10.27 | 9.79 | 9.79 |
Rasio Utama
ROA (TTM)
-36,4%
P/S (TTM)
7,57
P/B
2,4
EPS (TTM)
$-2,81
CF/Share
$-0,77
52W High
$24,35
52W Low
$10,57
$10,57
Rentang 52 Minggu
$24,35
Kesehatan Keuangan
Arus Kas Bebas
-$100.1M
Utang Bersih
-$168.6M
Kas
$205.3M
Total Utang
$36.8M
Per tanggal Des 31, 2025
Як DNLI виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка DNLI vs аналоги Biotechnology
P/E
—
▼
0%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
7,6
▼
41%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Undervalued
P/B
2,4
▼
3%
di bawah
rekan
(2,5)
vs Rekan
vs Industri
Nilai wajar
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість DNLI vs аналоги Biotechnology
ROE
-40,8%
▲
39%
di atas
rekan
(-67,3%)
vs Rekan
vs Industri
Di bawah rata-rata
Net margin
-36,5%
▲
87%
di atas
rekan
(-286,8%)
vs Rekan
vs Industri
Di bawah rata-rata
Валова маржа
—
▼
0%
di bawah
rekan
(78,6%)
vs Rekan
vs Industri
Sejajar
ROA
-36,4%
▲
22%
di atas
rekan
(-46,7%)
vs Rekan
vs Industri
Di bawah rata-rata
Фінансове здоровʼя DNLI vs аналоги Biotechnology
D/E ratio
0,6
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Sejajar
Поточна ліквідність
9,8
▲
121%
di atas
rekan
(4,4)
vs Rekan
vs Industri
Likuiditas kuat
Beta
1,0
▲
1%
di atas
rekan
(1,0)
vs Rekan
vs Industri
Kurang volatil
Радар фундаменталів DNLI
DNLI
Median rekan
Industri
DNLI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
DNLI vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
WATTS RYAN J
Chief Executive Officer · Jan 06
35198 shs
SCHUTH ALEXANDER O
Chief Financial Officer · Jan 06
17218 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 33,0%Vanguard Group Inc
8,23%
$237.1M
Blackrock Inc.
8,02%
$230.9M
BAILLIE GIFFORD & CO
7,76%
$223.6M
T. Rowe Price Investment Ma…
4,57%
$131.7M
Temasek Holdings (Private) …
4,42%
$127.4M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait